08:19 AM EST, 11/15/2024 (MT Newswires) -- Merck ( MRK ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of the company's Keytruda drug combined with pemetrexed and platinum chemotherapy to treat adults with unresectable non-epithelioid pleural mesothelioma.

The recommendation will be reviewed by the European Commission for marketing authorization in the European Union, with a final decision expected in Q4, Merck ( MRK ) said.

Price: 98.05, Change: -0.31, Percent Change: -0.32